Translational research in hepatic oncology
Featured projects
-
HUNTER-Hepatocellular Carcinoma Expediter Network CRUK, AEDD, AIRC Accelerator Award.
Principal investigator: Josep Mª Llovet Bayer.Code: AECC-Accelerator Award 2017.Duration: 01/01/2019 - 31/12/2023Summary:To decode the immunological landscape of HCC in tissue & blood & lead clinical translation in the community
Mecanismos de Resistencia adquirida a sorafenib en el carcinoma hepatocelular
Principal investigator: Josep Mª Llovet Bayer.Funder: National Health Institute, Spain. I+D Program, IIBB/IDIBAPS/CSIC (Sede); National Health Institute, Spain. ; IDIBAPS - Hospital Clínic (Sede).Code: (Grant number: SAF2016-76390-R).Duration: 01/01/2017 - 31/12/2020Translational in hepatic oncology research group
Principal investigator: Josep M Llovet Bayer.Funder: Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) .Code: 2017-SGR-01358.Duration: 01/01/2017 - 30/12/2020Mechanisms of acquired resistance to sorafenib in HCC.
Principal investigator: Dr Lowe Dr Lujambio Dr Villanueva Dr Josep M Llovet Friedman Dr.Funder: Mount Sinai School of Medicine (MSSM) (Sede); Department of Defense. USA ; Mount Sinai School of Medicine (MSSM) (Participante).Code: CA150272P1.Duration: 01/09/2016 - 31/08/2019Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities (HEP-CAR)
Principal investigator: Josep Mª Llovet Bayer.Code: 667273.Duration: 01/01/2016 - 31/12/2019The Tisch Cancer Institute: Cancer Center
Principal investigator: Steven J. Burakoff, Josep Mª Llovet Bayer.Funder: National Cancer Institute (NCI) (Sede); National Cancer Institute (NCI). 1P30CA165979-01 ; The Tisch Cancer Institute: Cancer Center (Sede).Code: 1P30CA165979-01.Duration: 09/01/2015 - 09/01/2020Summary:The mission of the Tisch Cancer Institute (TCI) at the Icahn School of Medicine at Mount Sinai (ISMMS) of New York is to advance the field of cancer research, treatment and prevention and to facilitate the availability of these advancements to our communities so as to extend and improve the lives of cancer patients and their families.
Oncogenic drivers and poor prognosis signatures
Principal investigator: Josep Maria Llovet Bayer.Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede).Code: SAF-2013-41027.Duration: 01/01/2014 - 01/01/2016Identification of new drivers as poor prognosis and assessment as therapeutic targets in hepatocellular carcinoma - (DRIVERS-HCC)
Principal investigator: J.M. Llovet.Funder: Ministerio de Economia y Competitividad (MINECO) .Code: SAF2013-41027-R.Duration: 01/01/2014 - 01/01/2016Integrative genomic analysis of intrahepatic cholangiocarcinoma (AECC_Grupo Estable 11)
Principal investigator: Josep Maria Llovet Bayer.Code: GCA110347LLOV.Duration: 01/09/2011 - 31/08/2018Genomic predictors and oncogenic drivers in hepatocellular carcinoma (HEPTROMIC)
More about researchCheck job offersIDIBAPS-FCRB looks for talented professionals to meet the needs that appear periodically.
Enter